Tolterodine
| Clinical data | |
|---|---|
| Trade names | Detrol, Detrusitol, others |
| Other names | PNU-200583E |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a699026 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 77% |
| Protein binding | Approximately 96.3% |
| Elimination half-life | 1.9–3.7 hours |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEBI |
|
| ChEMBL |
|
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.232.068 |
| Chemical and physical data | |
| Formula | C22H31NO |
| Molar mass | 325.496 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Tolterodine, sold under the brand name Detrol among others, is a medication used to treat frequent urination, urinary incontinence, or urinary urgency. Effects are seen within an hour. It is taken by mouth.
Common side effects include headache, dry mouth, constipation, and dizziness. Serious side effects may include angioedema, urinary retention, and QT prolongation. Use in pregnancy and breastfeeding are of unclear safety. It works by blocking muscarinic receptors in the bladder thus decreasing bladder contractions.
Tolterodine was approved for medical use in 1998. It is available as a generic medication. In 2020, it was the 271st most commonly prescribed medication in the United States, with more than 1 million prescriptions.